Increased AXLhigh myeloid cells as pathognomonic marker in Langerhans cell histiocytosis and Langerin expression dependence of mTOR inhibition
Clinical Immunology · 2024
DOI: 10.1016/j.clim.2024.110203 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Immunology, 2024. Verfasst von Cinthia Mariel Olexen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Medicina Experimental (IMEX), Academia Nacional de Medicina-CONICET, Buenos Aires 1425, Argentina; Instituto de Farmacología, Facultad d…. Hauptthemen laut MEDLINE: Antigens, CD, Axl Receptor Tyrosine Kinase, Histiocytosis, Langerhans-Cell, Lectins, C-Type. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Langerhans cell histiocytosis (LCH) is characterized by an expansion and accumulation of pathological histiocytes expressing langerin (CD207) and CD1a in different organs under an inflammatory milieu. The origin of pathognomonic precursors of LCH is widely debated, but monocytes and pre-dendritic cells (pre-DC) play a significant role. Remarkably, we found an expansion of AXLhigh cells in the CD11c+ subset of patients with active LCH, which also express the pathognomonic CD207 and CD1a. Moreover, we obtained a monocyte-derived LC-like (mo-LC-like) expressing high levels of AXL when treated with inflammatory cytokine, or plasma of patients with active disease. Intriguingly, inhibiting the mTOR pathway at the initial stages of monocyte differentiation to LC-like fosters the pathognomonic LCH program, highly increasing CD207 levels, together with NOTCH1 induction. We define here that AXLhigh could also be taken as a strong pathognomonic marker for LCH, and the release of Langerin and NOTCH1 expression depends on the inhibition of the mTOR pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Medicina Experimental (IMEX), Academia Nacional de Medicina-CONICET, Buenos Aires 1425, Argentina; Instituto de Farmacología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires 1121, Argentina.
- Instituto de Farmacología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires 1121, Argentina.
- Instituto de Farmacología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires 1121, Argentina; Hospital de Niños Pedro de Elizalde, Buenos Aires 1270, Argentina; Hospital de Clínicas General San Martin, Dep…
- Instituto de Farmacología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires 1121, Argentina. Electronic address: andreaerrasti@gmail.com.
- Instituto de Medicina Experimental (IMEX), Academia Nacional de Medicina-CONICET, Buenos Aires 1425, Argentina. Electronic address: carrerasilva@yahoo.com.ar.
Zitieren
APA
Olexen, C. M., Risnik, D., Lava, M. C., Dalla Vecchia, G. L., Rosso, D. A., Errasti, A. E., & Carrera Silva, E. A. (2024). Increased AXLhigh myeloid cells as pathognomonic marker in Langerhans cell histiocytosis and Langerin expression dependence of mTOR inhibition. Clinical Immunology. https://doi.org/10.1016/j.clim.2024.110203
Vancouver
Olexen CM, Risnik D, Lava MC, Dalla Vecchia GL, Rosso DA, Errasti AE, et al. Increased AXLhigh myeloid cells as pathognomonic marker in Langerhans cell histiocytosis and Langerin expression dependence of mTOR inhibition. Clinical Immunology. 2024. doi:10.1016/j.clim.2024.110203
BibTeX
@article{Olexen2024,
author = {Olexen, Cinthia Mariel and Risnik, Denise and Lava, María Catalina and Dalla Vecchia, Guido Luis and Rosso, Diego Alfredo and Errasti, Andrea Emilse and Carrera Silva, Eugenio Antonio},
title = {Increased AXLhigh myeloid cells as pathognomonic marker in Langerhans cell histiocytosis and Langerin expression dependence of mTOR inhibition},
journal = {Clinical Immunology},
year = {2024},
doi = {10.1016/j.clim.2024.110203}
}
EUVIMED